Shots: Celgene has added four more immunotherapies (making it eight, to 2017 deal) to develop and commercialize with an option to license WW IPR of the developed product, using Dragonfly’s TriNKET technology Dragonfly to get $50M upfront with milestones and royalties (if the option to license is exercised by Celgene) TriNKET technology (Tri-specific, NK cell […]Read More
